ANTX icon

AN2 Therapeutics

18 hedge funds and large institutions have $134M invested in AN2 Therapeutics in 2022 Q1 according to their latest regulatory filings, with 18 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.

Holders
18
Holders Change
+18
Holders Change %
% of All Funds
0.28%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
%
% of All Funds
0.02%
New
18
Increased
Reduced
Closed
Calls
Puts
Net Calls
Net Calls Change
Name Market Value Shares Shares
Change
Shares
Change %
RCM
1
RA Capital Management
Massachusetts
$55.3M 3,666,663 +3,666,663 New
BI
2
BVF Inc
California
$24.4M 1,616,665 +1,616,665 New
Citadel Advisors
3
Citadel Advisors
Florida
$20.6M 1,419,851 +1,419,851 New
APM
4
Avidity Partners Management
Texas
$10.4M 688,330 +688,330 New
DM
5
Deerfield Management
New York
$8.8M 584,136 +584,136 New
MIM
6
Monashee Investment Management
Massachusetts
$6.53M 433,330 +433,330 New
WP
7
Woodline Partners
California
$2.26M 150,000 +150,000 New
Alyeska Investment Group
8
Alyeska Investment Group
Illinois
$1.88M 125,000 +125,000 New
Vanguard Group
9
Vanguard Group
Pennsylvania
$1.13M 74,733 +74,733 New
Millennium Management
10
Millennium Management
New York
$1.12M 74,238 +74,238 New
CAC
11
Cowen and Company
New York
$908K 60,278 +60,278 New
Goldman Sachs
12
Goldman Sachs
New York
$294K 19,497 +19,497 New
Barclays
13
Barclays
United Kingdom
$275K 18,220 +18,220 New
Wellington Management Group
14
Wellington Management Group
Massachusetts
$250K 16,600 +16,600 New
AFM
15
Anson Funds Management
Texas
$38K 2,500 +2,500 New
UBS Group
16
UBS Group
Switzerland
$17K 1,158 +1,158 New
Morgan Stanley
17
Morgan Stanley
New York
$14K 885 +885 New
TRCT
18
Tower Research Capital (TRC)
New York
$10K 653 +653 New
CFGS
19
Concourse Financial Group Securities
Alabama